High expression of DEK predicts poor prognosis of gastric adenocarcinoma

Diagnostic Pathology

Zhenhua Lin³  Yuzi Li²  Xuelian Cui¹  Yingshi Piao³  Shuangping Liu³  Yongjun Shang⁴  Junjie Piao³ 

[1] Department of Pathology, Yanbian University Medical College, No. 977, Gongyuan-Rd, Yanji 133002, China;Department of Internal Medicine, Yanbian University Hospital, No. 1327, Juzi-St, Yanji 133000, China;Cancer Research Center, Yanbian University, Yanji 133002, China;Department of Orthopedics, Affiliated Hospital of Chifeng University, Chifeng 024000, China

关键词: Survival analysis;    Immunohistochemistry;    DEK;    Gastric adenocarcinoma;   

Others  :  802110
DOI  :  10.1186/1746-1596-9-67

 received in 2014-01-24, accepted in 2014-03-03,  发布年份 2014

【 摘 要 】

Background

DEK, as an oncoprotein, plays an important role in cancer development and progression. This study aimed to investigate the clinicopathological significance of DEK overexpression in patients with gastric cancer.

Materials and methods

The expression of DEK protein was evaluated by immunohistochemical (IHC) staining of 172 gastric cancer samples with complete clinicopathological features, and the correlation between DEK expression and clinicopathological features was examined. Survival rates were also calculated using the Kaplan-Meier method in gastric cancer patients with complete survival data.

Results

DEK protein showed a strictly nuclear staining pattern in gastric cancers with IHC and immunofluorescence. The strongly positive rate of DEK protein was 60.5% (104/172) in gastric cancers, which was significantly higher than that in either gastric dysplasia (19.4%, 7/36) or adjacent normal mucosa (0%, 0/27). DEK expression in gastric cancer correlated to tumor size, differentiation, clinical stage, disease-free survival, and overall survival rates. Further analysis showed that patients with early-stage gastric cancer and high DEK expression had shorter disease-free survival and overall survival duration than those with low DEK expression.

Conclusion

High level of DEK protein expression predicts the poor prognosis of patients with gastric cancer. DEK expression might be potentially used as an independent effective biomarker for prognostic evaluation of gastric cancers.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5050145571193097 webcite

【 授权许可】

   
2014 Piao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Wang T, Xuan X, Li M, Gao P, Zheng Y, Zang W, Zhao G: Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells. Diagn Pathol 2013, 8:179. BioMed Central Full Text
• [3]Gao M, Wang H, Wang G: The distinct expression patterns of claudin-10, −14, −17 and E-cadherin between adjacent non-neoplastic tissues and gastric cancer tissues. Diagn Pathol 2013, 8:205. BioMed Central Full Text
• [4]Geng M, Wang L, Chen X, Cao R, Li P: The association between chemosensitivity and Pgp. GST-π and Topo II expression in gastric cancer. Diagn Pathol 2013, 8:198. BioMed Central Full Text
• [5]Canzonieri V, Colarossi C, Del Col L, Perin T, Talamini R, Sigon R, Cannizzaro R, Aiello E, Buonadonna A, Italia F, Massi D, Carbone A, Memeo L: Exocrine and endocrine modulation in common gastric carcinoma. Am J Clin Pathol 2012, 137:712-721.
• [6]von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, Grosveld G: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, DEK and CAN, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992, 12:1687-1697.
• [7]Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R, Markovitz DM: The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011, 25:673-678.
• [8]Fu GK, Grosveld G, Markovitz DM: DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci U S A 1997, 94:1811-1815.
• [9]McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E, Nickerson JA, Awrey D, Greenblatt J, Grosveld G, Blencowe BJ: The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 2000, 150:309-320.
• [10]Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C: The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 2000, 14:1308-1312.
• [11]Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmüller L, Wells SI: The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 2011, 39:7465-7476.
• [12]Riveiro-Falkenbach E, Soengas MS: Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010, 16:2932-2938.
• [13]Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C: Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003, 163:505-516.
• [14]Casas S, Nagy B, Elonen E, Aventín A, Larramendy ML, Sierra J, Ruutu T, Knuutila S: Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 2003, 44:1935-1941.
• [15]Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 2013, 13:366. BioMed Central Full Text
• [16]Fléjou JF: WHO Classification of digestive tumors: the fourth edition. Ann Pathol 2011, 31:S27-S31.
• [17]Jin J, Jin T, Quan M, Piao Y, Lin Z: Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 7:135. BioMed Central Full Text
• [18]Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Müller H: DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006, 5:1202-1207.
• [19]Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009, 69:6405-6413.
• [20]Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR: The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000, 156:191-198.
• [21]Liu S, Wang X, Sun F, Kong J, Li Z, Lin Z: DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int 2012, 62:176-181.
• [22]Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP: Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 2011, 11:234. BioMed Central Full Text
• [23]Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C: Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004, 24:6011-6020.
• [24]Wang J, Sun L, Yang M, Luo W, Gao Y, Liu Z, Qiu X, Wang E: DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer. J Histochem Cytochem 2013, 61:510-521.
• [25]Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI: DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009, 174:71-81.
• [26]Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI: Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006, 26:7506-7519.
• [27]Sandén C, Ageberg M, Petersson J, Lennartsson A, Gullberg U: Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. BMC Cancer 2013, 13:440. BioMed Central Full Text